Shire’s Vyvanse Approved For ADHD
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will launch the drug in the second quarter pending final DEA clearance as a Schedule II controlled substance.
You may also be interested in...
ADHD Market Snapshot: Changes Blow In With Adderall XR Generics
The first generic versions of Shire's market-leading attention deficit/hyperactivity disorder medication Adderall XR (amphetamine extended release) are expected to hit the market April 1. This will deliver a kick to the remaining branded drugs in the category - though not as swiftly as some might expect
ADHD Market Snapshot: Changes Blow In With Adderall XR Generics
The first generic versions of Shire's market-leading attention deficit/hyperactivity disorder medication Adderall XR (amphetamine extended release) are expected to hit the market April 1. This will deliver a kick to the remaining branded drugs in the category - though not as swiftly as some might expect
FDA Approves Shire’s Once-daily Vyvanse For Adult ADHD
British biopharma had pegged nearly one-third of drug’s sales to off-label adult usage.